DM4-d6

For research use only. Not for therapeutic Use.

  • CAT Number: S000182
  • Molecular Formula: C38H48D6ClN3O10S
  • Molecular Weight: 786.4
  • Purity: ≥95%
Inquiry Now

DM4-d6, a premium pharmaceutical research compound designed for advanced oncology and cytotoxic studies. As a deuterated analog of DM4, it offers enhanced stability and improved pharmacokinetic properties. DM4-d6 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel antibody-drug conjugates (ADCs) and cancer therapies. Trusted by leading laboratories, DM4-d6 is your go-to solution for cutting-edge cancer research. Unlock new possibilities in cancer treatment with DM4-d6, where innovation meets reliability.


Catalog Number S000182
Molecular Formula C38H48D6ClN3O10S
Purity ≥95%
IUPAC Name [(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-3,3,3-trideuterio-2-[(4-methyl-4-sulfanylpentanoyl)-(trideuteriomethyl)amino]propanoate
InChI InChI=1S/C38H54ClN3O10S/c1-21-12-11-13-28(49-10)38(47)20-27(50-35(46)40-38)22(2)33-37(6,52-33)29(51-34(45)23(3)41(7)30(43)14-15-36(4,5)53)19-31(44)42(8)25-17-24(16-21)18-26(48-9)32(25)39/h11-13,17-18,22-23,27-29,33,47,53H,14-16,19-20H2,1-10H3,(H,40,46)/b13-11+,21-12+/t22-,23+,27+,28-,29+,33+,37+,38+/m1/s1/i3D3,7D3
InChIKey JFCFGYGEYRIEBE-LINSGLIMSA-N
SMILES [2H]C([2H])([2H])[C@@H](C(=O)O[C@H]1CC(=O)N(C2=C(C(=CC(=C2)C/C(=C/C=C/[C@H]([C@]3(C[C@@H]([C@H]([C@H]4[C@]1(O4)C)C)OC(=O)N3)O)OC)/C)OC)Cl)C)N(C(=O)CCC(C)(C)S)C([2H])([2H])[2H]
Reference

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[Content Brief]

[2]. Tang R, et al. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer. 2009 Jun 23;9:199.
[Content Brief]

Request a Quote